BVS vs REGN · rev $573.3M vs P/E 14, rev $14.34B
Bioventus Inc (BVS) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Bioventus Inc (BVS) is a medical devices company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported BVS revenue for 2024-12-31 was $573.3M. Net income was -$43.8M. Revenue was up 11.9% from 2023-12-31 to 2024-12-31. BVS currently screens at market cap $495.1M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
BVS currently screens at market cap $495.1M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the BVS and REGN stock pages for the full models.
Not investment advice.